Minerva Neurosciences Inc (NASDAQ:NERV) Director William F. Doyle purchased 1,800 shares of the stock in a transaction dated Monday, September 17th. The shares were purchased at an average price of $10.50 per share, with a total value of $18,900.00. Following the completion of the acquisition, the director now owns 12,011 shares of the company’s stock, valued at $126,115.50. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

NASDAQ NERV traded down $0.17 on Friday, reaching $9.75. The company’s stock had a trading volume of 199,907 shares, compared to its average volume of 188,389. Minerva Neurosciences Inc has a twelve month low of $4.80 and a twelve month high of $12.95. The company has a market capitalization of $486.62 million, a price-to-earnings ratio of -9.03 and a beta of 1.60.

Minerva Neurosciences (NASDAQ:NERV) last released its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.06. On average, sell-side analysts anticipate that Minerva Neurosciences Inc will post -1.39 EPS for the current year.

Large investors have recently added to or reduced their stakes in the stock. Highland Capital Management LP grew its holdings in Minerva Neurosciences by 4.0% during the first quarter. Highland Capital Management LP now owns 2,246,876 shares of the biopharmaceutical company’s stock valued at $14,043,000 after purchasing an additional 86,332 shares during the last quarter. BlackRock Inc. boosted its position in shares of Minerva Neurosciences by 11.2% in the second quarter. BlackRock Inc. now owns 2,181,703 shares of the biopharmaceutical company’s stock valued at $17,998,000 after acquiring an additional 219,405 shares during the period. Millennium Management LLC boosted its position in shares of Minerva Neurosciences by 2.8% in the second quarter. Millennium Management LLC now owns 919,471 shares of the biopharmaceutical company’s stock valued at $7,586,000 after acquiring an additional 25,092 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Minerva Neurosciences by 40.4% in the second quarter. Dimensional Fund Advisors LP now owns 391,041 shares of the biopharmaceutical company’s stock valued at $3,226,000 after acquiring an additional 112,461 shares during the period. Finally, Northern Trust Corp boosted its position in shares of Minerva Neurosciences by 18.7% in the second quarter. Northern Trust Corp now owns 358,803 shares of the biopharmaceutical company’s stock valued at $2,960,000 after acquiring an additional 56,592 shares during the period. Hedge funds and other institutional investors own 71.96% of the company’s stock.

A number of research analysts have recently commented on the stock. BidaskClub cut shares of Minerva Neurosciences from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. ValuEngine raised shares of Minerva Neurosciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 23rd. Finally, Citigroup boosted their target price on shares of Minerva Neurosciences to $19.00 in a research note on Friday, August 3rd.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.

Featured Story: Day Trading

Insider Buying and Selling by Quarter for Minerva Neurosciences (NASDAQ:NERV)

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.